Clinical Trial Update: Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bevacizumab for unresectable nonmetastatic hepatocellular carcinoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-29